Zobrazeno 1 - 10
of 1 429
pro vyhledávání: '"S. Herbst"'
Autor:
C. Schmidt, M. Janssen, P.-M. Bruch, M. F. Blank, C. Rohde, A. Waclawiczek, S. Renders, D. Heid, S. Göllner, L. Vierbaum, K. Weidenauer, S. Herbst, M. Knoll, C. Kolb, B. Besenbeck, M. Fabre, M. Gu, R. Schlenk, F. Stölzel, M. Bornhäuser, C. Röllig, U. Platzbecker, C. Baldus, H. Serve, T. Sauer, S. Raffel, C. Pabst, G. Vassiliou, B. Vick, I. Jeremias, A. Trumpp, J. Krijgsveld, C. Müller-Tidow, S. Dietrich
Publikováno v:
HemaSphere, Vol 6, Pp 354-355 (2022)
Externí odkaz:
https://doaj.org/article/33037fcd597e45c7b7f220536d15a99a
Autor:
M. Guenther, F. Altenkirch, K. Ostermann, G. Rödel, I. Tobehn-Steinhäuser, S. Herbst, S. Görlandt, G. Gerlach
Publikováno v:
Journal of Sensors and Sensor Systems, Vol 8, Pp 215-222 (2019)
Whole-cell biosensors, based on genetically modified yeast cells, were employed to detect anthropogenic micropollutants (e.g. drugs). Specific stimuli, e.g. traces of drugs, lead to the induction of fluorescence in the respective cells. Receptors of
Externí odkaz:
https://doaj.org/article/3c5324ab6d924ef5a97f8d9cc3c05f60
Autor:
Douglas I. Lin, Richard S. P. Huang, Ioannis Ladas, Rachel B. Keller, Nimesh R. Patel, Sotirios Lakis, Brennan Decker, Tyler Janovitz, Douglas A. Mata, Jeffrey S. Ross, Jo-Anne Vergilio, Julia A. Elvin, Roy S. Herbst, Philip C. Mack, Jonathan K. Killian
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundWhile many molecular assays can detect mutations at low tumor purity and variant allele frequencies, complex biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and genomic loss of heterozygosity (gLOH) requi
Externí odkaz:
https://doaj.org/article/f00911dcecc04bac98bd66bb18ec2b34
Autor:
Rakesh Kumar, Roy S Herbst, Sarah Goldberg, Zachary A Cooper, Kurt Schalper, Kerryan Ashley, Krishna Iyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a7e152ea4b8e44d0b8b7ee6725a2604d
Autor:
Robert Johnston, Hartmut Koeppen, Roy S Herbst, Kurt Schalper, Filippo De Marinis, Giuseppe Giaccone, Jacek Jassem, Marcus Ballinger, Barani Kumar Rajendran, David R Spigel, Miguel López de Rodas, Minu K Srivastava, Jennifer M Giltnane, Barzin Y Nabet, David S Shames, Velimir Gayevskiy, Vy Ma, Ivette Estay, Tien Hoang, Reena Amin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/49316787c82b4055a76f2b4631e47f3f
Autor:
Rakesh Kumar, Roy S Herbst, Sarah Goldberg, Zachary A Cooper, Kurt Schalper, Kerryan Ashley, Krishna Iyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f0f9a2cb242d4d6da01e7f48ddc82b84
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs), including those targeting programmed cell death protein-1 and its ligand
Externí odkaz:
https://doaj.org/article/9d8184a679e344cc9413ecfe3b104672
Autor:
Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 8, Pp 100205- (2021)
Introduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive non–small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the
Externí odkaz:
https://doaj.org/article/4253c840bb3a4ea2a990a5ad8dd55f52
Autor:
Amy Burd, Richard L. Schilsky, John C. Byrd, Ross L. Levine, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Mary W. Redman, Brian J. Druker, David R. Gandara
Publikováno v:
Blood Advances, Vol 3, Iss 14, Pp 2237-2243 (2019)
Abstract: The appetite for cutting-edge cancer research, across medical institutions, scientific researchers, and health care providers, is increasing based on the promise of true breakthroughs and cures with new therapeutics available for investigat
Externí odkaz:
https://doaj.org/article/1cd08a7cb2754c7491bebd002f449233
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186a6cc4f094b6d28c76ddac63f92a21
https://doi.org/10.1200/jco.22.02543
https://doi.org/10.1200/jco.22.02543